CN107669691A - Monose wood sugar product is preparing the application in preventing and treating urinary system infection contamination medicine - Google Patents
Monose wood sugar product is preparing the application in preventing and treating urinary system infection contamination medicine Download PDFInfo
- Publication number
- CN107669691A CN107669691A CN201711189898.1A CN201711189898A CN107669691A CN 107669691 A CN107669691 A CN 107669691A CN 201711189898 A CN201711189898 A CN 201711189898A CN 107669691 A CN107669691 A CN 107669691A
- Authority
- CN
- China
- Prior art keywords
- xylose
- urinary system
- monose
- system infection
- infection contamination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to monose xylose（D‑xylose）Application in urinary system infection contamination is prevented and treated.Prove that D xylose can effectively prevent the combination of avian pathogenic Escherichia coli and bladder cells and nephrocyte by Cell Biology Experiment and zoopery, and field planting of the avian pathogenic Escherichia coli in bladder is significantly reduced in Mice Body, the effect of urinary system infection contamination caused by there is prevention and treatment avian pathogenic Escherichia coli.
Description
Technical field
The invention belongs to pharmaceutical preparation applied technical field, is related to monose wood sugar product and is preparing prevention and treatment urinary system
Application in system infection medicine.
Background technology
Urinary tract infection（UTI, urinary tract infections）It is one of most common bacterial infection disease, disease
Urinary tract infection caused by indigenous bacteria can cause acute simplex cystitis, acute simplex pyelonephritis, complexity urinary tract infection,
The clinical common urinary system infection contamination disease such as repeated relapsing urinary tract infection.It is reported that about 40% women and 12% man
Property can at least undergo once Symptomatic urinary tract infection in life, wherein the 6-12 middle of the month that 10% women can be after infection
Recurrent infection again.Statistics shows that the whole world has more than more than 1,000 ten thousand urinary system infection contamination case every year.Urinary system togetherness
One of dye and important hospital infection, account for United States Hospital infection and bacteremic first place.Urinary system caused by pathogenetic bacteria
Infection also brings huge social economical burden, only by taking the statistics in the U.S. as an example, in terms of spending in its treatment every year
Expense reaches as many as 3,500,000,000.Therefore, prevent and the infection of control urinary system pathogenetic bacteria is global urgent problem to be solved.
The pathogenetic bacteria for causing urinary system infection contamination is mainly gramnegative bacterium, including Escherichia coli, proteus,
Providence Salmonella, pseudomonas aeruginosa etc..The Escherichia coli of urinary tract infection can be triggered, and to be named as urethra pathogenic big
Enterobacteria（UropathogenicEscherichia coli, UPEC）.Urinary system infection contamination caused by UPEC accounts for pure
More than the 80% of infection.Living environment of the urinary system infection contamination bacterium in human body is more special, and pathogenetic bacteria is established thin to host
The infection of born of the same parents is firstly the need of the scouring force of urine in resistance urethra, antibacterial material etc. caused by urine and urothelial cell, this
The urinary system malignant bacteria needs of pyelonephritis are caused to go upward to kidney along urethra outside, therefore urinary system pathogenetic bacteria generally has
There is abundant surface antigen, and fimbrial antigen is to meet the bacterium effectively key effect factor of adhesion and systemic infection.
Fimbrial antigen is widely present in urinary system infection contamination bacterium surface, special with the acceptor of host's urinary system epithelial cell
The opposite sex combines, and mediates further invasion and attack.The structure of pili has conservative, but the adhesin on pili top in species level
With polymorphism, the specificity combined with host receptor is determined.In addition, fimbrial antigen also has immunogenicity and antigenicity,
As the target of urinary system infection contamination bacterial vaccine research and development.Fimbrial antigen top adhesin is how sugar-modified with host cell surface
Antigen binding.Have been reported and show that mannoside can target I type fimbrial antigens, trigger so as to suppress avian pathogenic Escherichia coli
Urinary system infection contamination.Therefore, monosaccharide components prevent pathogen from adhering to and infect uropoiesis possibly through targeting fimbrial antigen
System epithelium, so as to reduce the generation of urinary system infection contamination.
Monose xylose（D-xylose）For pentose, be present in the form of polysaccharide in plant, exist in animal heparin,
In chondroitin and glycoprotein, it is sugar chain and serine in some glycoprotein（Or threonine）Connection unit.Monose xylose can
Obtained by the plant rich in hemicellulose such as wood chip, straw, corncob through hydrolysis.
It is difficult to be decomposed by human consumption's enzyme system after xylose intake, saliva, gastric juice, pancreatic juice and intestinal fluid etc. are all hardly
Xylose can be decomposed, is a kind of sweetener of empty calory, tolerance is preferable, and excessive eat will not cause abdominal distension and diarrhoea, can be used as
The raw material of diet food and regulation blood glucose food.Xylose is not also utilized by Institute of Micro-biology in oral cavity, will not cause carious tooth, possess meals
The part physiological function of fiber is eaten, serum cholesterol and prevention intestinal cancer can be reduced.Xylose is advantageous to the bifid bar in human body intestinal canal
The existence of the beneficial bacteriums such as bacterium, edible xylose can improve the microbial environment of human body, improve the immunocompetence of body.Xylose and food
Compatibility it is fine, can add in any proportion in food as needed, and good health-care effect can be embodied.Wood
Sugar is a kind of reproducibility carbohydrate, and reduction generation xylitol is hydrogenated under catalyst action, and its purposes is more extensive.Xylose is with it
Raw material sources are abundant, function is excellent and the advantages such as added value is high, it has also become promising health-care food ingredient.With people couple
The understanding of xylose improves, and its application also can be more and more wider.But it is used to prevent and treat urinary system infection contamination on xylose
There is not yet document report.
The content of the invention
It is an object of the invention to establish a kind of method for preventing and treating urinary system infection contamination.Implementation disclosed by the invention
Mode meets this purpose.
To achieve the above object, the invention discloses following technology contents：
Monose xylose D-xylose or product containing D-xylose are preparing the application in preventing and treating urinary system infection contamination medicine.
Wherein described urinary system infection contamination refers to：Acute urinary caused by UPEC.Cell experiment result shows D-
Xylose can significantly reduce the interaction of UPEC bacterial strains and Urothelial Cell and renal epithelial cell, and results of animal is also demonstrate,proved
It is real to give the processing of xylose gavage before and after UPEC infects C57BL/6J mouse and significantly reduce field planting of the bacterium in bladder.
The present invention further discloses the pharmaceutical composition of monose xylose D-xylose or the product containing D-xylose and should
Application of the composition in the medicine for preparing prevention and treatment urinary system infection contamination, mainly can pharmaceutically be connect by addition
The pharmaceutic adjuvant received is prepared into hard shell capsules, soft capsule, tablet, granule, powder, supensoid agent or syrup, wherein the tablet bag
Include：Dispersible tablet, lozenge, chewable tablets or effervescent tablet.
The present invention further discloses monose xylose D-xylose or product containing D-xylose and secreted for preparing protection
Application in the medicine of urinary system health.Described product containing D-xylose generally refers to pharmaceutically acceptable by adding
Hard shell capsules, soft capsule, tablet, granule, powder, supensoid agent or the syrup that pharmaceutic adjuvant is prepared into, wherein the tablet includes：
Dispersible tablet, lozenge, chewable tablets or effervescent tablet.
Prepared by the pharmaceutical composition of the present invention is mainly prepared into ebonite by adding pharmaceutically acceptable pharmaceutic adjuvant
Capsule, soft capsule, tablet, granule, powder, supensoid agent or syrup, wherein the tablet includes：Dispersible tablet, lozenge, chewable tablets or
Effervescent tablet.
Pharmaceutically acceptable pharmaceutic adjuvant can serve as diluent, flavouring agent, solubilizer, lubricant, suspending agent, bonding
Agent, disintegrant and coating agent.Such as：Magnesium phosphate, magnesium stearate, smoothers sugar, lactose, pectin, propane diols, polyoxyethylene sorbitan monoleate,
Dextrin, microcrystalline cellulose, starch, hydroxyl methylcellulose, gelatin, Sodium carboxymethyl starch, talcum powder, sodium pyrosulfite, low melting point
Paraffin, polyethylene glycol, mannitol, cocoa butter, aspartame etc..
Embodiment of the present invention is related to D-xylose to prevent and treat the method for urinary system infection contamination.
Embodiment is as follows：
1）Xylose solution is jointly processed by the cell of human bladder epithelium 5637 or people's kidney epithelium 786-O cells with CFT073 bacterial strains, passes through
The field planting bacterium amount of coated plate counting statistics each group；
2）The h of 30 min or rear 3 give the processing of the mg/kg xyloses gavage of mouse 100, a timing before UPEC per urethra infecting mouses
Between after put to death mouse take bladder to carry out tissue homogenate, pass through the field planting bacterium amount of coated plate counting statistics each group.
Embodiment of above has effectively prevented and treated urinary system infection contamination, and avoids traditional based on antibiotic
The shortcomings that therapeutic scheme.Thus, current embodiment will not facilitate the generation of multi-drug resistant bacterial strain, will not be in intestines and stomach
Microorganism species have detrimental effect.
Components D-xylose of the present invention has excellent processing characteristics and a variety of physiological regulation functions, is widely used
In various functions food, therefore there is very high security to human body, patient groups, which take, can treat disease, health worker's clothes
With can also play protective effect.
Brief description of the drawings
Effects of Fig. 1 D-xylose in CFT073 infects Urothelial Cell 5637 and renal epithelial cell 786-O；
Effects of Fig. 2 D-xylose in UPEC clinical separation strains infect Urothelial Cell 5637；
Fig. 3 C57BL/6J mouse give the D-xylose contents in certain time in urine after D-xylose gavages；
Fig. 4 C57BL/6J mouse give changes of weight situation in D-xylose gavages latter week；
Fig. 5 gives D-xylose C57BL/6J mouse in advance, and after UPEC infection, field planting of the bacterium in bladder significantly reduces；
After Fig. 6 UPEC infection C57BL/6J mouse, giving D-xylose significantly reduces the field planting of the UPEC in infecting mouse bladder.
Embodiment
The present invention is described below by specific embodiment.Unless stated otherwise, technological means used in the present invention is
Method known in those skilled in the art.In addition, embodiment is interpreted as illustrative, to be not intended to limit the present invention model
Enclose, the spirit and scope of the invention are limited only by the claims that follow.To those skilled in the art, without departing substantially from this hair
On the premise of bright spirit and scope, the various changes or change that are carried out to the material component in these embodiments and dosage also belong to
In protection scope of the present invention.Raw materials used and reagent of the invention is commercially available.
Embodiment 1
Effects of the D-xylose in CFT073 infects Urothelial Cell 5637 and renal epithelial cell 786-O
1) a little bacterium solution is taken from strain preservative tube, streak inoculation 37 °C, is incubated overnight in Luria-Bertani solid plates.
2) the monoclonal bacterium colony of picking LB solid plates, 5 ml LB fluid nutrient mediums is inoculated in, 37 °C, are incubated overnight.
3) 1 ml bacterium solutions are taken into 1.5 ml centrifuge tubes, 6000 rpm are centrifuged 5 minutes and collected thalline, supernatant discarding, PBS
Wash, thalline is resuspended with corresponding cell culture medium.
4) different bacterium MOI values and different D-xylose concentration is set to be incubated 2 jointly with 5637 and 786-O cells small
When.
5) culture supernatant is discarded, PBS is washed 5 times, and 0.2% Triton X-100 are cracked 10 minutes, collect lysate.
6) gradient dilution is carried out to above-mentioned lysate, is coated on non-resistant LB solid plates, 37 °C are incubated overnight.12-16
After hour, bacterium colony counting is carried out to flat board.
As a result show, D-xylose reduces CFT073 and Urothelial Cell and kidney epithelium in a manner of concentration dependant
The interaction of cell, reduce UPEC field planting.
Embodiment 2
Effects of the D-xylose in UPEC clinical separation strains infect Urothelial Cell 5637
1) a little bacterium solution is taken from strain preservative tube, streak inoculation 37 °C, is incubated overnight in LB solid plates.
2) the monoclonal bacterium colony of picking solid plate, 5 ml LB fluid nutrient mediums is inoculated in, 37 °C, are incubated overnight.
3) 1ml bacterium solutions are taken into 1.5 mL centrifuge tubes, 6000 rpm are centrifuged 5 minutes and collected thalline, supernatant discarding, PBS
Wash, thalline is resuspended with corresponding cell culture medium.
4) it is incubated altogether 2 hours with 0.5 mg/ml D-xylose and different UPEC clinical separation strains and 5637 cells.
5) culture supernatant is discarded, PBS is washed 5 times, and 0.2% Triton X-100 are cracked 10 minutes, collect lysate.
6) gradient dilution is carried out to above-mentioned lysate, is coated on non-resistant LB solid plates, 37 °C are incubated overnight.12-16
After hour, bacterium colony counting is carried out to flat board.
As a result show, compared with PBS groups, 0.5 mg/ml D-xylose can be significantly reduced on different clinical strains and bladder
The interaction of chrotoplast.
Embodiment 3
C57BL/6J mouse give the D-xylose contents in certain time in urine after D-xylose gavages
The C57BL/6J female mices of 6-8 week old sizes are chosen, the processing of 100 mg/kg D-xylose gavages is given, collects 0-6 hours
Interior urine, the D-xylose contents in urine are determined by phloroglucin colour developing.
As a result show, D-xylose contents reach highest in urine in 1-2 hours after gavage, D-xylose bases after 6 hours
This is discharged with urine.
Embodiment 4
C57BL/6J mouse give changes of weight situation in D-xylose gavages latter week
The C57BL/6J female mices of 6-8 week old sizes are chosen, give the processing of 100 mg/kg D-xylose gavages, are monitored small in one week
The changes of weight situation of mouse.
As a result show, mouse weight is stable after gavage, slightly increases, and in good condition, illustrates to give 100 mg/kg
D-xylose（Then the dosage of synthesized human is 11 mg/kg）Gavage processing has no toxic side effect to mouse.
Embodiment 5
D-xylose C57BL/6J mouse are given in advance, and after UPEC infection, field planting of the bacterium in bladder significantly reduces
The C57BL/6J female mices of 6-8 week old sizes are chosen, 100 mg/kg D-xylose or PBS gavages is given and handles, after 30min
Per urethra inoculation 1 × 108CFU CFT073, mouse is put to death after 3 hours and takes bladder body to be homogenized, gradient dilution, is coated on
Non-resistant LB solid plates, 37 °C are incubated overnight, and bacterium colony counts.
As a result show, compared with gavage PBS, UPEC can be significantly reduced in wing by giving 100 mg/kg D-xylose processing
The field planting of Guang, illustrate that D-xylose can be used for urinary system infection contamination caused by preventing UPEC.
Embodiment 6
After UPEC infection C57BL/6J mouse, giving D-xylose significantly reduces the field planting of the UPEC in infecting mouse bladder
Choose the C57BL/6J female mices of 6-8 week old sizes, per urethra inoculation 1 × 108CFU CFT073,100 are given after 3 hours
The processing of mg/kg D-xylose or PBS gavage, mouse is put to death after 4 hours and takes bladder body to be homogenized, gradient dilution, is coated on
Non-resistant LB solid plates, 37 °C are incubated overnight, and bacterium colony counts.
As a result show, compared with gavage PBS, UPEC can be significantly reduced in wing by giving 100 mg/kg D-xylose processing
The field planting of Guang, illustrate that D-xylose can be used for acute urinary caused by treating UPEC.
Embodiment 7
The tablet of the every active component containing 100mg prepares as follows：
Dosage/piece D-xylose
100mg microcrystalline cellulose 55mg starch 45mg hydroxyl methylcelluloses
4mg Sodium carboxymethyl starch 5mg magnesium stearate 1mg talcum powder
Preparation technology：Appropriate each composition is taken, by active component, starch and cellulose sieving, and be sufficiently mixed, by hydroxyl first fiber
Plain solution mixes with above-mentioned powder, and sieving, obtained wet granular is in 50-60 DEG C of drying, by Sodium carboxymethyl starch, stearic acid
Magnesium and talcum powder sieve in advance, are then added to tabletting in above-mentioned particle.
Embodiment 8
D-xylose 0.3g mannitol 9.4g aspartames 0.2g
Sodium pyrosulfite 0.003g essence 0.1g
Preparation technology：Main ingredient and auxiliary material are crossed into 100 mesh sieves respectively.First auxiliary material is sufficiently mixed, then weigh recipe quantity auxiliary material with
Main ingredient is sufficiently mixed.Adhesive softwood is added, the granulation of 20 mesh sieves, 55 DEG C of dryings, 20 mesh sieve whole grains, fine powder is sifted out, packs.
The above described is only a preferred embodiment of the present invention, any formal limitation not is made to the present invention, it is all
It is any simple modification, equivalent change and modification made according to the technical spirit of the present invention to above example, still falls within
In the range of technical solution of the present invention.
Claims (5)
1. monose xylose D-xylose or product containing D-xylose answering in prevention and treatment urinary system infection contamination medicine is prepared
With.
2. the application described in claim 1, wherein described urinary system infection contamination refers to：Avian pathogenic Escherichia coli causes
Acute urinary.
3. a kind of pharmaceutical composition containing the monose xylose D-xylose described in claim 1 or the product containing D-xylose, its
It is characterised by that adding pharmaceutically acceptable pharmaceutic adjuvant is prepared into hard shell capsules, soft capsule, tablet, granule, powder, supensoid agent
Or syrup, wherein the tablet includes：Dispersible tablet, lozenge, chewable tablets or effervescent tablet.
4. the pharmaceutical composition of the D-xylose of xylose containing monose described in claim 3 or the product containing D-xylose is for preparing
Prevent and treat the application in the medicine of urinary system infection contamination.
5. the pharmaceutical composition of the D-xylose of xylose containing monose described in claim 3 or the product containing D-xylose is for preparing
Protect the application in the medicine of urinary system health.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711189898.1A CN107669691A (en) | 2017-11-24 | 2017-11-24 | Monose wood sugar product is preparing the application in preventing and treating urinary system infection contamination medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711189898.1A CN107669691A (en) | 2017-11-24 | 2017-11-24 | Monose wood sugar product is preparing the application in preventing and treating urinary system infection contamination medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107669691A true CN107669691A (en) | 2018-02-09 |
Family
ID=61150422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711189898.1A Pending CN107669691A (en) | 2017-11-24 | 2017-11-24 | Monose wood sugar product is preparing the application in preventing and treating urinary system infection contamination medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107669691A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115475173A (en) * | 2022-10-31 | 2022-12-16 | 浙江华康药业股份有限公司 | Application of D-xylose in preparation of medicines for improving intestinal tract mucosa inflammation and resisting early diabetes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056380A2 (en) * | 2002-12-23 | 2004-07-08 | Forum Bioscience Holdings Limited | Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation |
| CN104474143A (en) * | 2014-11-18 | 2015-04-01 | 卢艳东 | Traditional Chinese medicine composition for treating hepatitis B and preparation method thereof |
-
2017
- 2017-11-24 CN CN201711189898.1A patent/CN107669691A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056380A2 (en) * | 2002-12-23 | 2004-07-08 | Forum Bioscience Holdings Limited | Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation |
| CN104474143A (en) * | 2014-11-18 | 2015-04-01 | 卢艳东 | Traditional Chinese medicine composition for treating hepatitis B and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115475173A (en) * | 2022-10-31 | 2022-12-16 | 浙江华康药业股份有限公司 | Application of D-xylose in preparation of medicines for improving intestinal tract mucosa inflammation and resisting early diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20110124780A (en) | Prebiotic formulations and methods of use | |
| US20060127381A1 (en) | Live bacterial preparation of bacillus coagulans for the treatment of ulcerative colitis, method for producing the same and use thereof | |
| CN104922586B (en) | A kind of preparation and its application of the probiotics fermention Chinese medicine preparation for preventing chicken coccidiasis | |
| CN106176833A (en) | A kind of prevent and treat diabetes the compound probiotic liquid controlling body weight and preparation method thereof | |
| CN105685970A (en) | Compound nutritious food capable of improving whole digestive tract | |
| CN113577218A (en) | Inactivated probiotic traditional Chinese medicine composition for inhibiting helicobacter pylori and preparation method and application thereof | |
| KR20070062007A (en) | Anti-ulcer composition containing fermented extract of saccharified rice or glutinous rice and preparation method thereof | |
| WO2023142877A1 (en) | Use of bacteroides fragilis in improvement and treatment of diarrhea | |
| CN106138114A (en) | A kind of preparation method of composite probiotics preparations prevented and treated diabetes and control body weight | |
| CN100500176C (en) | Chinese medicine composition with functions of expelling surficial evils and clearing away heat and toxic materials and its preparing method and application | |
| KR20200018532A (en) | Lactobacillus sp. strain having inhibitory effect against microorganisms causing vaginosis uses thereof | |
| KR0145553B1 (en) | Treatment of clostridium difficile diarrhoea and pseudomembranous colitis | |
| CN101134052A (en) | Application of clostridium butyricum, condensate bacillus and bifidobacteria in the preparation of medicament for preventing and treating mouth ulcer | |
| CN107669691A (en) | Monose wood sugar product is preparing the application in preventing and treating urinary system infection contamination medicine | |
| KR20040014058A (en) | Microorganisms for Obesity or Diabetes Mellitus | |
| Guslandi | Probiotics for chronic intestinal disorders | |
| US8063026B2 (en) | Method of palliating lower urinary tract infections by treatment with mannan oligosaccharides | |
| CN116966206A (en) | Use of lactobacillus fermentum for the preparation of a product for the prevention and/or treatment of the colon of a laxative | |
| CN104013649A (en) | Bacillus licheniformis symbiotic composition and preparations thereof | |
| JP4509250B2 (en) | Helicobacter pylori sanitizing medicine | |
| CN115844019A (en) | Probiotic capable of regulating intestinal tract and application | |
| KR101373770B1 (en) | Pharmaceutical composition comprising Angelica dahurica Bentham et Hook extract for preventing or treating infectious disease of Enterohamorrhagic Escherichia coli | |
| CN107126453A (en) | A kind of composition for preventing and treating urinary system infection contamination | |
| JP2796635B2 (en) | Immune enhancer | |
| CN113924107B (en) | Yeast-containing composition for preventing simple and/or recurrent cystitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180209 |
|
| WD01 | Invention patent application deemed withdrawn after publication |